These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 31672491)
41. Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma. Ohmura S; Grünewald TGP Clin Cancer Res; 2024 Aug; 30(16):3358-3360. PubMed ID: 38861280 [TBL] [Abstract][Full Text] [Related]
42. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308 [TBL] [Abstract][Full Text] [Related]
43. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells. Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354 [TBL] [Abstract][Full Text] [Related]
44. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma. Sankar S; Tanner JM; Bell R; Chaturvedi A; Randall RL; Beckerle MC; Lessnick SL Mol Cell Biol; 2013 Nov; 33(22):4448-60. PubMed ID: 24043308 [TBL] [Abstract][Full Text] [Related]
45. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018 [TBL] [Abstract][Full Text] [Related]
46. Genetically Engineered Mouse Model in Ewing Sarcoma. Tanaka M; Nakamura T Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102 [TBL] [Abstract][Full Text] [Related]
47. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells. Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567 [TBL] [Abstract][Full Text] [Related]
48. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability. Keskin T; Bakaric A; Waszyk P; Boulay G; Torsello M; Cornaz-Buros S; Chevalier N; Geiser T; Martin P; Volorio A; Iyer S; Kulkarni A; Letovanec I; Cherix S; Cote GM; Choy E; Digklia A; Montemurro M; Chebib I; Nielsen PG; Carcaboso AM; Mora J; Renella R; Suvà ML; Fusco C; Provero P; Rivera MN; Riggi N; Stamenkovic I Cell Rep; 2020 Mar; 30(13):4567-4583.e5. PubMed ID: 32234488 [TBL] [Abstract][Full Text] [Related]
49. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330 [TBL] [Abstract][Full Text] [Related]
50. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9. Fidaleo M; Svetoni F; Volpe E; Miñana B; Caporossi D; Paronetto MP Oncotarget; 2015 Oct; 6(31):31740-57. PubMed ID: 26450900 [TBL] [Abstract][Full Text] [Related]
51. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency. Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849 [TBL] [Abstract][Full Text] [Related]
52. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553 [TBL] [Abstract][Full Text] [Related]
53. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142 [TBL] [Abstract][Full Text] [Related]
55. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Pessetto ZY; Chen B; Alturkmani H; Hyter S; Flynn CA; Baltezor M; Ma Y; Rosenthal HG; Neville KA; Weir SJ; Butte AJ; Godwin AK Oncotarget; 2017 Jan; 8(3):4079-4095. PubMed ID: 27863422 [TBL] [Abstract][Full Text] [Related]
56. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021 [TBL] [Abstract][Full Text] [Related]
57. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein. Paronetto MP; Bernardis I; Volpe E; Bechara E; Sebestyén E; Eyras E; Valcárcel J Cell Rep; 2014 May; 7(4):1211-26. PubMed ID: 24813895 [TBL] [Abstract][Full Text] [Related]
58. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186 [TBL] [Abstract][Full Text] [Related]
59. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Prieur A; Tirode F; Cohen P; Delattre O Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325 [TBL] [Abstract][Full Text] [Related]
60. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle. Asami S; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T Biol Pharm Bull; 2008 Mar; 31(3):391-4. PubMed ID: 18310898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]